CN-120732881-B - Application of hyperin and salvianolic acid B in combined preparation of NAFLD (NAFLD-mediated disease) treatment drug

Abstract

The invention relates to an application of hyperin and salvianolic acid B in preparing a medicament for treating NAFLD in a combined way, and belongs to the technical field of biological medicines. When the hyperin and the salvianolic acid B are combined to be used in the required amount for treatment, the hyperin and the salvianolic acid B have synergistic effect in preparing the medicaments for treating the nonalcoholic fatty liver disease, and the combined use of the hyperin and the salvianolic acid B can enhance the curative effect, reduce the side effect and be greater than the effect of single medicament, thereby providing a new idea for treating the nonalcoholic fatty liver disease and having important significance and wide application prospect.

Inventors

• WANG SONGSONG
• HAN LIWEN
• ZHOU ZIRONG
• LI YAXING
• YANG YING
• LI HUI

Assignees

• 山东第一医科大学(山东省医学科学院)

Dates

Publication Date

20260508

Application Date

20250903

Claims (4)

1. 1. The application of the combination of hyperin and salvianolic acid B in preparing the medicament for treating and/or preventing NAFLD is characterized in that the concentration of salvianolic acid B is 2.5-5 mu M, the concentration of hyperin is 3.75-7.5 mu M, and the molar ratio of salvianolic acid B to hyperin is 2:3.
2. 2. The medicine for preventing and/or treating NAFLD is characterized in that the active ingredients of the medicine comprise hyperoside and salvianolic acid B, the concentration of the salvianolic acid B is 2.5-5 mu M, the concentration of the hyperoside is 3.75-7.5 mu M, and the molar ratio of the salvianolic acid B to the hyperoside is 2:3.
3. 3. A medicament for the prophylaxis and/or treatment of NAFLD according to claim 2, wherein said medicament contains one or more pharmaceutically acceptable carriers or adjuvants.
4. 4. The drug for preventing and/or treating NAFLD according to claim 2, wherein the dosage form of the drug is an oral liquid or an injection.

Description

Application of hyperin and salvianolic acid B in combined preparation of NAFLD (NAFLD-mediated disease) treatment drug Technical Field The invention relates to an application of hyperin and salvianolic acid B in preparing a medicament for treating NAFLD in a combined way, and belongs to the technical field of biological medicines. Background Nonalcoholic fatty liver disease (NAFLD) is liver steatosis caused by nonalcoholic causes, and is a typical liver manifestation of metabolic syndrome. NAFLD incidence increases year by year, and further develops into steatohepatitis, liver cirrhosis, and even liver cancer, which has become one of the important causes of chronic liver disease. The main current therapeutic strategy is through life intervention, with only resmetirom approved by the FDA for NAFLD treatment in 2024, which is very limited. Therefore, development of a novel therapeutic drug with high efficiency and low toxicity is highly demanded. Hyperoside (hyperoside, hyp) is a flavonol glycoside compound, and the prior researches show that the hyperin can obviously reduce the content of free bile acid in rat liver by activating liver FXR protein, thereby relieving the toxic effect of bile acid on the liver, and simultaneously has the effects of promoting the excretion of lipid and bile acid, accelerating the oxidation of fatty acid, inhibiting the synthesis of lipid and the like. The pharmacological action of the hyperin suggests that the hyperin can be applied to NAFLD in a new field, however, the hyperin has the problems of unstable drug effect and insignificant anti-inflammatory action along with the deep research, and the application of the hyperin is limited. Sal B (salvianolic acid B, sal B) is a hydrophilic active ingredient extracted from Saviae Miltiorrhizae radix, and is a natural polyphenol compound with pharmacological effects of resisting tumor, thrombosis, fibrosis, inflammation, and oxidation, and protecting heart, liver, cranial nerve, and blood vessel. Meanwhile, it was found in the prior studies that Sal B at a certain concentration can improve non-alcoholic fatty liver disease, especially in terms of lipid regulation. In the mechanism research, salvianolic acid B can inhibit the expression of intestinal LIMA1 protein, and LIMA1 protein is proved to play a role in the transportation process of cholesterol transport protein NPC1L1 from an endocytic circulation body to a cell membrane, so that the ingestion of cholesterol is influenced. Up to now, hyperin combined with salvianolic acid B has not been applied in the treatment of non-alcoholic fatty liver disease. Disclosure of Invention Aiming at the defects of the prior art, the invention provides an application of hyperin and salvianolic acid B in preparing medicines for treating NAFLD in a combined way. The technical scheme adopted by the invention is as follows: The application of hyperin and salvianolic acid B in preparing medicines for treating and/or preventing NAFLD is provided. According to the invention, when the salvianolic acid B is administrated at a cell level, the concentration of salvianolic acid B is 2.5-5 mu M, the concentration of hyperin is 3.75-7.5 mu M, and the molar ratio of salvianolic acid B to hyperin is 2:3. According to the present invention, the salvianolic acid B concentration is preferably 10mg/kg and the hyperoside concentration is preferably 1.5mg/kg when administered on an animal level basis. A medicine for preventing and/or treating NAFLD comprises hyperin and salvianolic acid B as effective components. According to the invention, when the salvianolic acid B is administrated at a cell level, the concentration of salvianolic acid B is 2.5-5 mu M, the concentration of hyperin is 3.75-7.5 mu M, and the molar ratio of salvianolic acid B to hyperin is 2:3. According to the present invention, the salvianolic acid B concentration is preferably 10mg/kg and the hyperoside concentration is preferably 1.5mg/kg when administered on an animal level basis. Preferably, according to the present invention, the medicament comprises one or more pharmaceutically acceptable carriers or adjuvants. Further preferably, the auxiliary agent is at least one of a sustained release agent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption enhancer, a surfactant, or a lubricant. Preferably, according to the invention, the dosage form of the medicament is a tablet, a pill, a capsule, an oral liquid or an injection. The beneficial effects are that: When hyperin and salvianolic acid B are combined to be used in the required amount for treatment, the hyperin and salvianolic acid B have synergistic effect in preparing medicaments for treating the nonalcoholic fatty liver disease, and the combined use of the hyperin and salvianolic acid B can enhance the curative effect, reduce side effects and be greater than the effect of single medicament, thereby providing a new idea for treating the nonalcoholic fatty liver